EVP Capital Management
VC Fund
Frankfurt, Germany
EVP Capital Management is a VC fund in Frankfurt focused on Software and Biotechnology. EVP Capital Management AG ist eine Private Equity Gesellschaft, die als Tochter der Co-Investor AG in mittelständische Technologieunternehmen in der Wachstumsphase investiert. Dabei konnte das Team der EVP umfassende Transaktionserfahrung vom Eingehen bis zum Veräußern von Beteiligungen aufbauen.Über die bis heute sechs aufgelegten Fonds undzusammen mit nahestehenden Privatinvestoren investieren wir in schnell wachsende Technologieunternehmen in der DACH-Region, denen wir neben Kapital auch wertvolle unternehmerische Unterstützung bieten, wobei die unternehmerische Eigenständigkeit erhalten bleibt.Hervorgegangen ist die heutige EVP Capital Management AG aus dem Anfang 2008 erfolgten Management Buy Out der equinet Venture Partners AG, dem Venture Capital Arm der Frankfurter Investmentbank equinet AG. Seitdem ist die EVP Capital Management AG eine 100%-Tochter der Co-Investor AG, Schweiz (www.co-investor.com)
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries EVP Capital Management invests in
Stages EVP Capital Management invests in
Countries EVP Capital Management invests in
Investment Focus
Industry
- Software 3 (38%)
- Biotechnology 2 (25%)
- Information Technology 2 (25%)
- SaaS 1 (13%)
- Medical 1 (13%)
Stage
- Series C 3 (38%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series A 1 (13%)
- Funding Round 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Calcs.com
|
ClearCalcs is an online SaaS for lightning fast creation and automation of engineering computations. With a powerful online math engine, ClearCalcs enables the fast, accurate creation of engineering calculations using natural math notation that is automatically converted into reusable entry forms. ClearCalcs' unique CAD plugin takes existing2D CAD drawings and automates the creation, calculation, and sizing of structural members, saving engineers substantial time while improving quality and cost-effectiveness. | $1.7M / Seed / Nov 19, 2021 | |
bio.logis
|
bio.logis Genetic Information Management (GIM) GmbH is part of the bio.logis Group and was founded in November 2013.bio.logis GIM translates genetic data into usable medical information and makes it available to physicians and patients. To that end, it has developed a special "Genetic Information Management Suite" (GIMS) IT solutionwhich, in the process chain required for genetic diagnostics, focuses on the "last mile“ to physicians and patients by merging genetic raw data with actionable clinical knowledge for prompt application. GIMS supports physicians in laboratories for automatically generating such expert content, as well as hospitals with specific clinical suggestions. | $4.7M / Series B / Dec 20, 2011 | |
Phenex Pharmaceuticals
|
Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen.Their company focuses its small-molecule drug discovery expertise in Liver andGastrointestinal disease areas and has now recently entered the field of Cancer Therapy. They not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities. Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules. | $6.6M / Series C / Sep 21, 2010 | |
|
Phenex Pharmaceuticals
|
Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen.Their company focuses its small-molecule drug discovery expertise in Liver andGastrointestinal disease areas and has now recently entered the field of Cancer Therapy. They not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities. Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules. | $9M / Series B / Oct 02, 2008 | |
Signature Diagnostics GmbH
|
Signature Diagnostics AG is a translational oncology and genomics company based in Potsdam, Germany. Founded in 2004, Signature develops large tumor tissue and plasma biobanks in multiple cancers, including colorectal and lung cancer in the framework of large multicenter prospective clinical studies. A key aspect of the translational oncology workis Signature's biobanks with longitudinal plasma samples from cancer patients. The company also develops several next generation sequencing (NGS) assays using targeted gene panels1. Signature has expertise in developing ultra-deep sequencing tests utilizing cfDNA, which may advance the development of non-invasive treatment response monitoring for cancer patients. | $5.6M / Series C / Aug 12, 2008 | |
fg microtec
|
fg microtec GmbH provides multimedia applications for 2.5G, 3G, and WLAN mobile phones. Its products include OMA/IMS compliant push-over-cellular clients, IMS and SIP based VoIP solutions, videotelephony, and video sharing over 3G and WLAN networks. The company also provides embedded software solutions, push to talk over cellular solutions,embedded applications, layered architectures, OMA enabler conformance tests, and data streams and protocols. It serves mobile phone manufacturers. The company was founded in 2000 and is based in Munich, Germany with an additional office in Zagreb, Croatia. | $2.6M / Aug 18, 2006 | |
Nova Ratio
|
The company was founded in 1995 as a service provider for projects and trainings in IT environments. Five years later it was turned into a corporation and started it's own software development. The board of share holders consists of private investors as well as the federal state of Rhineland-Palatinate.Today, the company founder anddeveloper of the eRunbook platform, Mr. Gerhard Wagner, is chairman of the board. | $1.3M / Series A / Apr 26, 2005 | |
iTAC Software
|
ITAC Software provides and develops manufacturing executing systems and solutions to the manufacturing industry. | $4.9M / Series C / Oct 06, 2004 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does EVP Capital Management invest in?
EVP Capital Management invests primarily in Software, Biotechnology and Information Technology startups, most often at Series C and Series B stage. Most of the 8 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did EVP Capital Management last invest?
The most recent investment recorded for EVP Capital Management closed in Nov 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
